Escherichia coli Infections - Pipeline Review, H2 2015 Is

Released
Escherichia coli Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Escherichia Coli
Infections - Pipeline Review, H2 2015, provides an overview of the Escherichia Coli Infectionss
therapeutic pipeline. This report provides comprehensive information on the therapeutic development
for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Escherichia Coli Infections and special features on latestage and discontinued projects. Global Markets Directs report features investigational drugs from
across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Directs proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets Direct s team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box and clinical trials registries
tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated disease. Scope - The report provides a
snapshot of the global therapeutic landscape of Escherichia Coli Infections - The report reviews key
pipeline products under drug profile section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental activities - The report reviews key players
involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and
minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of
the Escherichia Coli Infections products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources - Pipeline products
coverage based on various stages of development ranging from pre-registration till discovery and
undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration
and molecule type - Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective
R&D development strategies - Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by
understanding the focus areas of leading companies - Identify and understand important and diverse
types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions
effectively by identifying key players of the most promising pipeline - Devise corrective measures for
pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication
therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business potential and scope - Modify
1

the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173367/escherichiacoli-infections-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173367/escherichia-coli-infections-pipeline-review-h2-2015

Table of Contents

Introduction 8
Global Markets Direct Report Coverage 8
Escherichia coli Infections Overview 9
Therapeutics Development 10
Pipeline Products for Escherichia coli Infections - Overview 10
Pipeline Products for Escherichia coli Infections - Comparative Analysis 11
Escherichia coli Infections - Therapeutics under Development by Companies 12
Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 16
Escherichia coli Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Escherichia coli Infections - Products under Development by Companies 20
Escherichia coli Infections - Products under Investigation by Universities/Institutes 23
Escherichia coli Infections - Companies Involved in Therapeutics Development 24
Adenium Biotech ApS 24
Arsanis Biosciences GmbH 25
AstraZeneca Plc 26
AvidBiotics Corp. 27
Bioorganic Research and Services S.A. 28
Cellceutix Corporation 29
2

Chiesi Farmaceutici SpA 30

Debiopharm International S.A. 31
Emergent BioSolutions Inc. 32
F. Hoffmann-La Roche Ltd. 33
GangaGen Inc. 34
GlaxoSmithKline Plc 35
Immuron Limited 36
Melinta Therapeutics, Inc 37
Microbiotix, Inc. 38
MicuRx Pharmaceuticals, Inc. 39
Mucosis B.V. 40
Navigen Pharmaceuticals, Inc. 41
Nosopharm SAS 42
Novabiotics Limited 43
Nymox Pharmaceutical Corporation 44
Pherecydes Pharma SA 45
Phico Therapeutics Limited 46
Procarta Biosystems Ltd 47
Sanofi Pasteur SA 48
Sealife PHARMA GMBH 49
Sequoia Sciences, Inc. 50
Soligenix, Inc. 51
Syntiron LLC 52
Tetraphase Pharmaceuticals Inc. 53
Trana Discovery, Inc. 54
Varinel, Inc. 55

Escherichia coli Infections - Therapeutics Assessment 56

Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
A-3APO - Drug Profile 65
AA-139 - Drug Profile 67
ACE-920 - Drug Profile 68
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 69
ASN-4 - Drug Profile 70
AvR2-V10 - Drug Profile 72
BIZ-20131 - Drug Profile 74
BIZ-20132 - Drug Profile 75
BIZ-20133 - Drug Profile 76
BNT-006 - Drug Profile 77
CC-1807 - Drug Profile 78
Debio-1454 - Drug Profile 79
Drugs for Bacterial Infections - Drug Profile 80
dusquetide - Drug Profile 81
EcoXyn-4V - Drug Profile 83
enterotoxigenic escherichia coli vaccine - Drug Profile 84
Escherichia coli (whole cell) vaccine - Drug Profile 85
Escherichia coli vaccine - Drug Profile 86
Escherichia coli vaccine - Drug Profile 87
ETEC Vaccine - Drug Profile 88
4

ETEC vaccine - Drug Profile 89

EV-035 - Drug Profile 90
GN snare - Drug Profile 92
GN-4474 - Drug Profile 93
IMM-363 - Drug Profile 94
INX-201 - Drug Profile 95
JNJ-63871860 - Drug Profile 96
MBX-2319 - Drug Profile 97
MDN-0057 - Drug Profile 98
MRX-V - Drug Profile 100
NBTI-5463 - Drug Profile 101
NOSO-95179 - Drug Profile 102
NP-432 - Drug Profile 103
NXC-4720 - Drug Profile 104
Onc-72 - Drug Profile 105
PMX-1241 - Drug Profile 106
PMX-1278 - Drug Profile 107
PMX-1363 - Drug Profile 108
PMX-1405 - Drug Profile 109
PMX-247 - Drug Profile 110
PMX-843 - Drug Profile 111
PP-0121 - Drug Profile 112
Proteins for Infectious Diseases - Drug Profile 114
PT-4 - Drug Profile 115
Recombinant Protein for Escherichia Coli Infections - Drug Profile 116
RX-05 - Drug Profile 117

RXP-873 - Drug Profile 118

SE-1 - Drug Profile 119
Shigetec - Drug Profile 120
SLP-0901 - Drug Profile 121
SLP-0905 - Drug Profile 122
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 123
Small Molecules for Bacterial Infections - Drug Profile 124
Small Molecules for Escherichia Coli Infections - Drug Profile 125
Small Molecules for Escherichia coli Infections - Drug Profile 126
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug
Profile 127
Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 128
Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 130
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 131
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
132
Synthetic Peptides for Escherichia Coli Infections - Drug Profile 133
TP-6076 - Drug Profile 134
VAR-10100 - Drug Profile 135
Escherichia coli Infections - Recent Pipeline Updates 136
Escherichia coli Infections - Dormant Projects 143
Escherichia coli Infections - Discontinued Products 146
Escherichia coli Infections - Product Development Milestones 147
Featured News & Press Releases 147
Appendix 148
Methodology 148
Coverage 148
6

Secondary Research 148

Primary Research 148
Expert Panel Validation 148
Contact Us 148
Disclaimer 149

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173367/escherichia-coliinfections-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects